<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03067883</url>
  </required_header>
  <id_info>
    <org_study_id>Master (No 142)</org_study_id>
    <nct_id>NCT03067883</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Qurevo Plus Ribavirin Based Therapy for Hepatitis C With or Without Cirrhosis in Haemodialysis Patients</brief_title>
  <official_title>Evaluation of Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir Plus Ribavirin Based Therapy for Chronic Hepatitis C With or Without Compensated Cirrhosis in Haemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate efficacy and safety of Ombitasvir, paritaprevir, and ritonavir plus ribavirin&#xD;
      based therapy for chronic hepatitis C with or without compensated cirrhosis in haemodialysis&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is;&#xD;
&#xD;
      To evaluate the efficacy and safety of ombitasvir, paritaprevir, and ritonavir based therapy&#xD;
      for chronic hepatitis C with or without compensated cirrhosis in HCV treatment naïve patients&#xD;
      receiving long-term haemodialysis through assessment of:&#xD;
&#xD;
        1. The proportion of patients with a sustained virological response (HCV RNA &lt;25 IU/mL) 12&#xD;
           weeks after the last dose of study drug (SVR12).&#xD;
&#xD;
        2. To determine withdrawal rate related to side effects and /or adverse effects for&#xD;
           patients receiving at least 1 dose of the study medication.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">November 9, 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, cohort, open label trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained Virological Response</measure>
    <time_frame>After 12 weeks after the last dose</time_frame>
    <description>The proportion of patients with a sustained virological response (HCV RNA &lt;25 IU/mL) 12 weeks after the last dose of study drug (SVR12).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment related withdrawal rate</measure>
    <time_frame>during treatment period, average duration 3 months</time_frame>
    <description>To determine withdrawal rate related to side effects and /or adverse effects for patients receiving at least 1 dose of the study medication.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Chronic Hepatitis c</condition>
  <arm_group>
    <arm_group_label>interventional Qurevo group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A total of 40 HCV treatment naïve patients with or without compensated cirrhosis on regular hemodialysis will be enrolled in the study.&#xD;
These patients will receive intervention of '25 mg ombitasvir, 150 mg paritaprevir, and 100 mg ritonavir' (2 capsules Qurevo®) plus ribavirin 200 mg daily for 12 weeks.&#xD;
Qurevo will be given once daily (on the day of dialysis, it will be given after dialysis session).&#xD;
Ribavirin will be given once daily (on the day of dialysis, it will be given 4 hrs before dialysis session ).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ombitasvir, Paritaprevir and Ritonavir</intervention_name>
    <description>A total of 40 HCV treatment naïve patients with or without compensated cirrhosis on regular hemodialysis will be enrolled in the study.&#xD;
These patients will receive an intervention of '25 mg ombitasvir, 150 mg paritaprevir, and 100 mg ritonavir' (2 capsules Qurevo®) plus ribavirin 200 mg daily for 12 weeks.&#xD;
Qurevo will be given once daily (on the day of dialysis, it will be given after dialysis session).&#xD;
Ribavirin will be given once daily (on the day of dialysis, it will be given 4 hrs before dialysis session ).</description>
    <arm_group_label>interventional Qurevo group</arm_group_label>
    <other_name>qurevo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Under regular HD for at least 6 months&#xD;
&#xD;
          2. Clinically stable condition as outpatients.&#xD;
&#xD;
          3. Treatment naïve patients with serum positive for HCV GT4 with HCV RNA &gt; 1000 IU/ml by&#xD;
             PCR.&#xD;
&#xD;
          4. White blood cell count &gt; 2500/mm^3.&#xD;
&#xD;
          5. Platelet count &gt; 7500/mm^3.&#xD;
&#xD;
          6. Patients categorised as having compensated cirrhosis had a diagnosis of cirrhosis&#xD;
             based on a previous screening liver FibroTest score of 0·72 or lower (eg, Metavir&#xD;
             Fibrosis Score &gt;3 [including 3/4 or 3-4] ).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Confirmed pregnancy.&#xD;
&#xD;
          2. HCV-HIV co infection.&#xD;
&#xD;
          3. HBV-HCV co infection.&#xD;
&#xD;
          4. Uncontrolled hyper or hypothyroidism.&#xD;
&#xD;
          5. For patients without cirrhosis, Patients will be excluded if alanine or aspartate&#xD;
             aminotransferase more than five times the upper limit of normal, for patients with&#xD;
             cirrhosis they will be excluded if alanine or aspartate aminotransferase are higher&#xD;
             than seven times the upper limit of normal&#xD;
&#xD;
          6. Patients on peritoneal dialysis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mai Mohamed Naguib Abd Elmen'em, B.pharm</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maadi armed forces hospital</name>
      <address>
        <city>Cairo</city>
        <state>Maadi</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maadi armed forces hospital</last_name>
      <phone>002025265127</phone>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>January 23, 2017</study_first_submitted>
  <study_first_submitted_qc>February 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2017</study_first_posted>
  <last_update_submitted>January 17, 2018</last_update_submitted>
  <last_update_submitted_qc>January 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Mai Mohamed Naguib Abdelmen'em Mohamed</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

